Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + chemotherapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2400082102Phase 2Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by First Hospital of China Medical University. Primary endpoint: Major pathological response (MPR). Started Mar 2024; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400082102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082102.